Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance.
- Author:
Jing YANG
1
;
Juan DU
1
;
Yu Xiang WANG
1
;
Cong Rong LIU
1
Author Information
1. Department of Pathology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
High-grade serous carcinoma;
Janus kinases;
Ovarian neoplasms;
Signal transducer and activator of transcription
- MeSH:
Humans;
Prognosis;
STAT5 Transcription Factor/metabolism*;
Neoplasms;
Signal Transduction;
Immunohistochemistry
- From:
Journal of Peking University(Health Sciences)
2023;55(2):270-275
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:The activation of Janus kinase (JAK) and signal transducers and activators of transcription (STAT) plays an important role in the prognosis and targeted therapy of ovarian high-grade serous carcinoma (HGSC). Utilizing simple and practicable technique, this study aimed to evaluate the activation of JAK/STAT signaling pathway in ovarian HGSC patients, and investigated the correlation between the activation of JAK/STAT signaling pathway and the prognosis of the HGSC patients.
METHODS:We performed immunohistochemistry of phosphorylated STAT3 (pSTAT3) and phosphorylated STAT5 (pSTAT5) on paraffin imbedded slides of 73 ovarian HGSC patients, and evaluated the expression level and range of both markers. According to the grading score of the immunostaining of pSTAT3 and pSTAT5, we divided the 73 ovarian HGSC cases into STAT3 low/high expression and STAT5 low/high expression groups, and analyzed the prognosis of the patients in different groups, in order to explore the relationship between the expression of pSTAT3 and pSTAT5 proteins and the prognosis of the HGSC patients.
RESULTS:Some of the ovarian HGSC cases showed high expression of pSTAT3 and pSTAT5 protein level, which was related to the poorer prognosis of the HGSC patients. There was a significant difference in the expression level of pSTAT3 and pSTAT5 between the patients with better prognosis (survival time ≥3 years) and poorer prognosis (survival time < 3 years). The patients with higher protein expression of pSTAT3, pSTAT5 or both markers might have poorer prognosis, with significant shorter progression-free survival time and overall survival time (P < 0.001).
CONCLUSION:Immunostaining of pSTAT3 and pSTAT5 proteins might be helpful to evaluate and predict the prognosis of the ovarian HGSC patients, and to identify the patients who might have higher chances to respond to the STAT inhibitors and anti-angiogenesis therapy.
